Results from Cohorts 4 and 5 of the Phase 2 KEYNOTE-199 Study Published

Jun 30

Written By Kristofer Prepelica, PhD

Kristofer Prepelica, PhD

PCCTC-managed Phase 1 Study of K36’s Novel NSD2 Inhibitor KTX-2001 Activated

Prognostic Significance of PSA>0.2 After 6-12 Months Treatment for mHSPC Intensified by ARPIs: A Multinational Real-World Analysis of the IRONMAN Registry